Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CoronaVac in Healthy Adults
NCT04953325Phase 4Completed
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of coronavac in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoint: Seroconversion rate of the neutralizing antibody to SARS-CoV-2. Started Jul 2021; status: completed.
02
Drugs
coronavac
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04953325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953325.